FFM
KROS icon

Fairmount Funds Management’s Keros Therapeutics KROS Stock Holding History

Fairmount Funds Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-272,498
Closed -$10.3M – 24
2022
Q3 		$10.3M Hold
272,498
– – 1.8% 20
2022
Q2 		$7.53M Sell
272,498
-124,413
-31% -$5.46M 1.72% 21
2022
Q1 		$21.6M Buy
396,911
+104,078
+36% +$5.34M 5.1% 8
2021
Q4 		$17.1M Buy
292,833
+143,500
+96% +$7.16M 5.65% 8
2021
Q3 		$5.91M Hold
149,333
– – 2.15% 19
2021
Q2 		$6.34M Buy
149,333
+40,000
+37% +$2.17M 2.61% 17
2021
Q1 		$6.73M Buy
+109,333
New +$6.93M 2.84% 17

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Fairmount Funds Management's KROS Position: Q4 2022 in Review

Fairmount Funds Management sold out of Keros Therapeutics (KROS) in Q4 2022, closing a stake of 272,498 shares — an estimated $10.3M sold.

Fairmount Funds Management first reported a position in KROS in Q1 2021 and held it in 7 quarters. The position peaked at $21.6M in Q1 2022. 126 funds tracked by Wall St. Rank hold KROS as of Q4 2022.

  • Fairmount Funds Management reported no remaining Keros Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Fairmount Funds Management sold 272,498 Keros Therapeutics shares in Q4 2022, an estimated $10.3M.
  • Fairmount Funds Management first reported a position in Keros Therapeutics in Q1 2021 and held it in 7 quarters.
  • Fairmount Funds Management's Keros Therapeutics position peaked at $21.6M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2022.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.